Company Overview

Home/Company Overview

Our vision at Neopharmed Gentili: aid people in living a long and healthy life.

Neopharmed Gentili is an Italian pharmaceutical company that has historically operated within its national borders and is currently in the process of expanding internationally.
It deals with bringing to market solutions of high therapeutic value, characterized by a concrete and tangible impact across multiple therapeutic areas.

Company Timeline


Corporate Vision
Our vision at Neopharmed Gentili is to aid people in living a long and healthy life.
Research, responsibility, and care:
Neopharmed Gentili’s mission places people at the core of the company’s daily commitment.

  • The patients, for whom it conducts research and studies on proven treatments and therapies.
  • Healthcare professionals, to whom it wants to be a trusted partner and provide continued support in terms of expertise.
  • To the individuals that make up the company, so they may feel they are part of a large organization that cares about the wellbeing of its staff and share a common goal: health and quality of life.

The unwavering commitment to the development of services with high therapeutic value at Neopharmed Gentili is bolstered by a daily emphasis on ethical value and scientific precision in the company’s operations.

These are the principles have guided Neopharmed Gentili since its founding in nurturing its culture, work, and identity.

In the past 10 years, Neopharmed Gentili has continued to grow at a steady rate thanks to its extraordinary financial operations and the strong collaborative partnerships that have been struck with other important multinational players such as MSD, whose ties to Neopharmed Gentili date back to the 1990s and their focus nowadays is primarily on Diabetes treatments. Other collaborations include Organon, an MSD spin-off and a strategic partner across several therapeutic areas, as well as Teva, a company with which Neopharmed Gentili has been collaborating in the respiratory market since 2017 for the development of Duoresp Spiromax.

Neopharmed Gentili, Research and therapeutic value with a focus on people.